JP2005512528A - １４１９、５８７６５および２２１０を用いて心血管疾患を処置するための方法および組成物 - Google Patents

１４１９、５８７６５および２２１０を用いて心血管疾患を処置するための方法および組成物 Download PDF

Info

Publication number
JP2005512528A
JP2005512528A JP2003551507A JP2003551507A JP2005512528A JP 2005512528 A JP2005512528 A JP 2005512528A JP 2003551507 A JP2003551507 A JP 2003551507A JP 2003551507 A JP2003551507 A JP 2003551507A JP 2005512528 A JP2005512528 A JP 2005512528A
Authority
JP
Japan
Prior art keywords
protein
nucleic acid
gene
activity
modulator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003551507A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005512528A5 (enExample
Inventor
トーマス ジョセフ ローガン，
ミョング チュン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of JP2005512528A publication Critical patent/JP2005512528A/ja
Publication of JP2005512528A5 publication Critical patent/JP2005512528A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
JP2003551507A 2001-12-10 2002-12-10 １４１９、５８７６５および２２１０を用いて心血管疾患を処置するための方法および組成物 Pending JP2005512528A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33999501P 2001-12-10 2001-12-10
PCT/US2002/039353 WO2003050504A2 (en) 2001-12-10 2002-12-10 Methods and compositions to treat cardiovascular disease usin g 1419, 58765 and 2201

Publications (2)

Publication Number Publication Date
JP2005512528A true JP2005512528A (ja) 2005-05-12
JP2005512528A5 JP2005512528A5 (enExample) 2006-02-02

Family

ID=23331451

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003551507A Pending JP2005512528A (ja) 2001-12-10 2002-12-10 １４１９、５８７６５および２２１０を用いて心血管疾患を処置するための方法および組成物

Country Status (5)

Country Link
US (2) US20030152574A1 (enExample)
EP (1) EP1451369A4 (enExample)
JP (1) JP2005512528A (enExample)
AU (1) AU2002360531A1 (enExample)
WO (1) WO2003050504A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI111745B (fi) * 2001-12-19 2003-09-15 Kemira Chemicals Oy Parannettu kartonginvalmistusmenetelmä
WO2003053363A2 (en) * 2001-12-19 2003-07-03 Millennium Pharmaceuticals, Inc. Human diacylglycerol acyltransferase 2 (dgat2) family members and uses therefor
US20050037946A1 (en) * 2003-01-13 2005-02-17 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cardiovascular disease using 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061, 17662, 1468, 12282, 6350, 9035, 1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123, 12788, 17729, 65552, 1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 41922, 2552, 2417, 19319, 43969, 8921, 8993, 955, 32345, 966, 1920, 17318, 1510, 14180, 26005, 554, 16408, 42028, 112091, 13886, 13942, 1673, 54946 or 2419
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
US7825235B2 (en) * 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
EP2057177B1 (en) 2006-08-04 2012-11-21 Isis Pharmaceuticals, Inc. Compositions and their uses directed to diacylglycerol acyltransferase 1
CN106661609B (zh) * 2013-11-27 2021-09-14 生物筛分及诊断学有限责任公司 用于预测先天性心脏缺陷的方法
ES2917181T3 (es) 2015-07-10 2022-07-07 Ionis Pharmaceuticals Inc Moduladores de diacilglicerol aciltransferasa 2 (DGAT2)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US161831A (en) * 1875-04-06 Improvement in processes of purifying galvanizers dross
US170691A (en) * 1875-12-07 Improvement in spring-equalizers
US5843749A (en) * 1991-07-26 1998-12-01 Regeneron Pharmaceuticals, Inc. Ehk and Ror tyrosine kinases
US5747033A (en) * 1993-10-28 1998-05-05 Regeneron Pharmaceuticals, Inc. Method of enhancing the biological activity of Eph family ligands
EP0756627A1 (en) * 1994-04-15 1997-02-05 Amgen Inc. Hek5, hek7, hek8, hek11, new eph-like receptor protein tyrosine kinases
DE69532857T2 (de) * 1994-10-27 2005-04-28 Genentech Inc., San Francisco Neurotrophischer AL-1 Faktor, einer Ligand verwandt mit dem EPH Tyrosine Kinase Receptor
US20030161831A1 (en) * 2001-02-23 2003-08-28 Sylvaine Cases Mono-and diacylglycerol acyltransferases and methods of use thereof
WO2003053363A2 (en) * 2001-12-19 2003-07-03 Millennium Pharmaceuticals, Inc. Human diacylglycerol acyltransferase 2 (dgat2) family members and uses therefor
WO2003065984A2 (en) * 2002-02-01 2003-08-14 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cardiovascular disease

Also Published As

Publication number Publication date
AU2002360531A8 (en) 2003-06-23
EP1451369A4 (en) 2006-09-20
WO2003050504A2 (en) 2003-06-19
US20050142604A1 (en) 2005-06-30
US20030152574A1 (en) 2003-08-14
AU2002360531A1 (en) 2003-06-23
WO2003050504A3 (en) 2003-11-20
EP1451369A2 (en) 2004-09-01

Similar Documents

Publication Publication Date Title
JP2007520996A (ja) ４４３９０、５４１８１、２１１、５６８７、８８４、１４０５、６３６、４４２１、５４１０、３０９０５、２０４５、１６４０５、１８５６０、２０４７、３３７５１、５２８７２、１４０６３、２０７３９、３２５４４、４３２３９、４４３７３、５１１６４、５３０１０、１６８５２、１５８７、２２０７、２２２４５、２３８７、５２９０８、６９１１２、１４９９０、１８５４７、１１５、５７９、１５９８５、１５６２５、７６０、１８６０３、２３９５、２５５４、８６７５、３２７２０、４８０９、１４３０３、１６８１６、１７８２７、３２６２０、５７７、６１９、１４２３、２１５８、８２６３、１５４０２、１６２０９、１６３８６、２１１６５、３０９１１、４１８９７、１６４３、２５４３、９６２６、１３２３１、３２４０９、８４２６０、２８８２、８２０３、３２６７８または５５０５３を用いて泌尿器科障害を処置するための方法および組成物
JP2005516605A (ja) 心血管疾患を処置するための方法および組成物
US20040091929A1 (en) Methods and compositions for the diagnosis and treatment of cardiovascular and tumorigenic disease using 4941
JP2006516895A (ja) １７２２、１０２８０、５９９１７、８５５５３、１０６５３、９２３５、２１６６８、１７７９４、２２１０、６１６９、１０１０２、２１０６１、１７６６２、１４６８、１２２８２、６３５０、９０３５、１８２０、２３６５２、７３０１、８９２５、８７０１、３５３３、９４６２、９１２３、１２７８８、１７７２９、６５５５２、１２６１、２１４７６、３３７７０、９３８０、２５６９６５４、３３５５６、５３６５６、４４１４３、３２６１２、１０６７１、２６１、４４５７０、４１９２２、２５５２、２４１７、１９３１９、４３９６９、８９２１、８９９３、９５５、３２３４５、９６６、１９２０、１７３１８、１５１０、１４１８０、２６００５、５５４、１６４０８、４２０２８、１１２０９１、１３８８６、１３９４２、１６７３、５４９４６、または２４１９を使用する、心血管疾患を処置するための方法および組成物
JP2005512528A (ja) １４１９、５８７６５および２２１０を用いて心血管疾患を処置するための方法および組成物
JP2005525112A (ja) ジアシルグリセロールキナーゼεを使用して疼痛を処置する際の方法および組成物
WO2002012887A2 (en) Methods and compositions for the diagnosis and treatment of brown adipose cell disorders
JP2005516604A (ja) １３１、１４８、１９９、１２３０３、１３９０６、１５５１３、１７８２２、３０２、５６７７、１９４、１４３９３、２８０５９、７３６６、１２２１２、１９８１、２６１、１２４１６、２７０、１４１０、１３７、１８７１、１３０５１、１８４７、１８４９、１５４０２、３４０、１０２１７、８３７、１７６１、８９９０または１３２４９分子を用いて血液障害を処置するための方法および組成物
US20060088881A1 (en) Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 molecules
JP2005507673A (ja) １３９、２５８、１２６１、１４８６、２３９８、２４１４、７６６０、８５８７、１０１８３、１０５５０、１２６８０、１７９２１、３２２４８、６０４８９または９３８０４を用いる心血管疾患を治療するための方法および組成物
US7169751B2 (en) Method of identifying a compound capable of treating a pain or a painful disorder
US20020151480A1 (en) Methods and compositions for treating cardiovascular disease using 10218
US20040180332A1 (en) Methods and compositions for treating aids and HIV-related disorders using 9145, 1725, 311, 837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397, 13644, 19938, 2077, 1735, 1786, 10220, 17822, 33945, 43748, 47161, 81982 or 46777
JP2005514013A (ja) １４６５、１５８７、２１４６、２２０７、３２８３８、３３６、および５２９０８を使用して疼痛および有痛性障害を処置する際の方法および組成物
US20030152970A1 (en) Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145
JP2005507665A (ja) ４６５６６を用いた疼痛障害の処置および診断のための方法および組成物
WO2001064872A2 (en) Gene 2465: methods and compositions for the diagnosis and treatment of cardiovascular, hepatic and bone disease
JP2005508172A (ja) フラクタルカインレセプターのモジュレーターを同定する方法、およびフラクタルカインレセプターのモジュレーターを使用する方法
US20020146686A1 (en) Methods and compositions for the diagnosis and treatment of viral disease using 55092
JP2005513054A (ja) ２５２、３０４、１９８０、１４７１７、９９４１、１９３１０、および１７８３２を用いて血液障害を処置するための方法および組成物
JP2005508173A (ja) ２３２、２０５９、１０６３０、１２８４８、１３８７５、１４３９５、１４６１８、１７６９２または５８８７４を使用する血液障害を処置するための方法および組成物
JP2005508638A (ja) ７１１８、ヒトアルギニンｎ−メチルトランスフェラーゼファミリーメンバーおよびその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20060713

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20060713

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20060713

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080722

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081015

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081022

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090317